These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 19879655

  • 1. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
    Brettschneider J, Jaskowski TD, Tumani H, Abdul S, Husebye D, Seraj H, Hill HR, Fire E, Spector L, Yarden J, Dotan N, Rose JW.
    J Neuroimmunol; 2009 Dec 10; 217(1-2):95-101. PubMed ID: 19879655
    [Abstract] [Full Text] [Related]

  • 2. Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis.
    Schwarz M, Spector L, Gortler M, Weisshaus O, Glass-Marmor L, Karni A, Dotan N, Miller A.
    J Neurol Sci; 2006 May 15; 244(1-2):59-68. PubMed ID: 16480743
    [Abstract] [Full Text] [Related]

  • 3. Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis.
    Verbeek MM, Notting EA, Faas B, Claessens-Linskens R, Jongen PJ.
    Acta Neurol Scand; 2010 May 15; 121(5):309-14. PubMed ID: 19925532
    [Abstract] [Full Text] [Related]

  • 4. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis.
    Frisullo G, Nociti V, Iorio R, Patanella AK, Marti A, Caggiula M, Mirabella M, Tonali PA, Batocchi AP.
    Cytokine; 2008 Oct 15; 44(1):22-5. PubMed ID: 18793860
    [Abstract] [Full Text] [Related]

  • 5. Anti-alpha-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event.
    Freedman MS, Laks J, Dotan N, Altstock RT, Dukler A, Sindic CJ.
    Mult Scler; 2009 Apr 15; 15(4):422-30. PubMed ID: 19324980
    [Abstract] [Full Text] [Related]

  • 6. Serum IgG and IgM ganglioside GM1 antibodies in patients with multiple sclerosis.
    Zaprianova E, Majtényi K, Deleva D, Mikova O, Filchev A, Sultanov B, Kolyovska V, Sultanov E, Christova L, Kmetska X, Georgiev D.
    Ideggyogy Sz; 2004 Mar 20; 57(3-4):94-9. PubMed ID: 15133910
    [Abstract] [Full Text] [Related]

  • 7. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C, Vukusic S.
    Brain; 2006 Mar 20; 129(Pt 3):606-16. PubMed ID: 16415308
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Increased serum levels of soluble CD14 indicate stable multiple sclerosis.
    Lutterotti A, Kuenz B, Gredler V, Khalil M, Ehling R, Gneiss C, Egg R, Deisenhammer F, Berger T, Reindl M.
    J Neuroimmunol; 2006 Dec 20; 181(1-2):145-9. PubMed ID: 17046070
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Patients with multiple sclerosis have higher levels of serum ghrelin.
    Berilgen MS, Bulut S, Ustundag B, Tekatas A, Ayar A.
    Neuro Endocrinol Lett; 2005 Dec 20; 26(6):819-22. PubMed ID: 16380704
    [Abstract] [Full Text] [Related]

  • 12. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis.
    Pasquali L, Lucchesi C, Pecori C, Metelli MR, Pellegrini S, Iudice A, Bonuccelli U.
    J Neuroimmunol; 2015 Jan 15; 278():53-9. PubMed ID: 25595252
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal.
    Montalban X, Sastre-Garriga J, Filippi M, Khaleeli Z, Téllez N, Vellinga MM, Tur C, Brochet B, Barkhof F, Rovaris M, Miller DH, Polman CH, Rovira A, Thompson AJ.
    Mult Scler; 2009 Dec 15; 15(12):1459-65. PubMed ID: 19995843
    [Abstract] [Full Text] [Related]

  • 15. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE, Sombekke M, van Winsen L, Killestein J, Barkhof F, Polman CH, Dijkstra CD, Blankenstein MA, Pratico D.
    Mult Scler; 2012 Aug 15; 18(8):1092-8. PubMed ID: 22695538
    [Abstract] [Full Text] [Related]

  • 16. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
    Pöhlau D, Przuntek H, Sailer M, Bethke F, Koehler J, König N, Heesen C, Späth P, Andresen I.
    Mult Scler; 2007 Nov 15; 13(9):1107-17. PubMed ID: 17623736
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Normal plasma antithrombin activity in patients with relapsing-remitting and secondary progressive multiple sclerosis.
    Campos-de-Magalhães M, de Almeida AJ, Papaiz-Alvarenga RM, Gadelha T, Morais-de-Sá CA, Alves-Leon SV.
    Clin Neurol Neurosurg; 2009 Jun 15; 111(5):407-11. PubMed ID: 19168277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.